8-K: Foghorn Therapeutics Reduces At-the-Market Offering Size to $100 Million

Foghorn Therapeutics amended its common stock sales agreement with TD Securities, reducing the potential offering size from $200 million to $100 million.

Summary

• Foghorn Therapeutics Inc. amended its Common Stock Sales Agreement with TD Securities (formerly Cowen and Company) on March 20, 2025.
• The amendment reduces the amount of common stock that may be sold under the at-the-market (ATM) program from $200 million to $100 million.
• The shares are being offered and sold pursuant to the company's effective shelf registration statement on Form S-3.
• The amendment updates the sales agent's name to TD Securities (USA) LLC and its address.
• The company is not party to any other at the market sales agreements.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While reducing the offering size might be seen as slightly negative, it could also indicate better capital management or a change in funding needs. The company is still able to raise capital through the ATM program.

Positives

• The company has an existing shelf registration statement in place, allowing for efficient access to capital.
• The company qualifies as an experienced issuer (within the meaning of FINRA Conduct Rule 5110(j)(6)) for purposes of the exemption from filing under FINRA Conduct Rule 5110(h)(1)(C).

Negatives

• The reduction in the offering size from $200 million to $100 million may indicate a decreased need for capital or less favorable market conditions.

Risks

• Market conditions may affect the company's ability to sell shares under the ATM program.
• Compliance with the share issuance limitation is the sole responsibility of the company.
• The company's compliance with Export and Import Laws is crucial to avoid potential claims, complaints, charges, investigations or proceedings.

Future Outlook

The company may issue and sell shares of its common stock through TD Cowen from time to time during the term of the agreement, subject to the terms and conditions outlined in the agreement and the applicable Placement Notice.

Industry Context

ATM offerings are a common method for biotech companies to raise capital, providing flexibility in timing and amount raised based on market conditions. Reducing the size of the offering could reflect a change in the company's capital needs or market conditions.

Comparison to Industry Standards

• Many biotech companies, such as Xometry Inc. and Amylyx Pharmaceuticals, utilize ATM offerings to raise capital.
• The size of the ATM offering ($100 million) is within the typical range for companies of Foghorn Therapeutics' size and stage.
• The terms of the agreement, including the sales agent's role and responsibilities, are standard for ATM offerings.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution if the company sells shares under the ATM program.
• The company's ability to fund its operations and research and development programs may be affected by the amount of capital raised through the ATM program.

Next Steps

• The company may sell shares of common stock through TD Cowen under the ATM program.
• The company will file a prospectus supplement with the Commission under Rule 424(b) under the Securities Act.
• The company will disclose the number of placement shares sold and the gross proceeds in its quarterly reports on Form 10-Q and annual report on Form 10-K.

Key Dates

Keywords

at-the-market offering, common stock, Foghorn Therapeutics, TD Securities, ATM program, Amendment, Sales Agreement